• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Director Laskawy Philip A sold $184,999 worth of shares (2,604 units at $71.04), decreasing direct ownership by 10% to 24,805 units (SEC Form 4)

    3/20/25 4:28:08 PM ET
    $HSIC
    Medical Specialities
    Health Care
    Get the next $HSIC alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    LASKAWY PHILIP A

    (Last) (First) (Middle)
    C/O HENRY SCHEIN, INC.
    135 DURYEA ROAD

    (Street)
    MELVILLE NY 11747

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    HENRY SCHEIN INC [ HSIC ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    03/19/2025
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock, par value $0.01 per share 03/19/2025 S 2,604 D $71.044(1) 24,805 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. The price reflects a weighted average of sales made at prices ranging from $71.01 to $71.05 per share. The Reporting Person, upon request by the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, will provide full information regarding the number of shares sold at each separate price for this transaction.
    /s/ Jennifer Ferrero (as attorney-in-fact for Philip A. Laskawy) 03/20/2025
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $HSIC alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $HSIC

    DatePrice TargetRatingAnalyst
    2/14/2025$80.00Equal Weight
    Wells Fargo
    1/6/2025$69.00 → $84.00Underperform → Buy
    BofA Securities
    12/4/2024$75.00Neutral
    Mizuho
    7/22/2024$81.00 → $92.00Neutral → Outperform
    Robert W. Baird
    2/26/2024$78.00Market Perform
    Leerink Partners
    12/12/2023$71.00 → $82.00Neutral → Overweight
    JP Morgan
    11/10/2023$70.00Hold → Buy
    Stifel
    8/8/2022$80.00Sell → Neutral
    UBS
    More analyst ratings

    $HSIC
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Henry Schein Inc.

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      11/13/24 3:30:01 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G filed by Henry Schein Inc.

      SC 13G - HENRY SCHEIN INC (0001000228) (Subject)

      11/12/24 9:32:27 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Henry Schein Inc. (Amendment)

      SC 13G/A - HENRY SCHEIN INC (0001000228) (Subject)

      2/14/24 11:18:57 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

      5/16/25 4:10:00 PM ET
      $HSIC
      $KKR
      Medical Specialities
      Health Care
      Investment Managers
      Finance
    • Henry Schein to Participate in Upcoming Investor Conference in June

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conference in June: Jefferies Global Healthcare Conference at the Marriott Marquis hotel, New York City, on June 4, 2025, at 1:20 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting https://investor.henryschein.com/webcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc. (NASDAQ:HSIC) is a solutions company for health care professionals powered by a network of people and techno

      5/15/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Participate in Upcoming Investor Conferences in May

      Henry Schein, Inc., the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following investor conferences in May: Bank of America Healthcare Conference at the Encore Hotel in Las Vegas on May 14, 2025, at 10:00 a.m. Pacific time (1:00 p.m. Eastern time). Stifel Jaws & Paws Conference at Lotte Hotel, New York City, on May 29, 2025, at 12:40 p.m. Eastern time. Henry Schein's presentations can be heard via live webcast by visiting www.henryschein.com/IRwebcasts. Replays will be available on the Henry Schein website following the presentations. About Henry Schein, Inc. Henry Schein, Inc

      5/6/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, CEO Bergman Stanley M gifted 1,140 units of Common Stock par value $0.01 per shre, decreasing direct ownership by 0.35% to 324,597 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      5/12/25 4:39:59 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • New insider Lin Max claimed no ownership of stock in the company (SEC Form 3)

      3 - HENRY SCHEIN INC (0001000228) (Issuer)

      5/8/25 4:10:36 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Director Laskawy Philip A sold $184,999 worth of shares (2,604 units at $71.04), decreasing direct ownership by 10% to 24,805 units (SEC Form 4)

      4 - HENRY SCHEIN INC (0001000228) (Issuer)

      3/20/25 4:28:08 PM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Financials

    Live finance-specific insights

    See more
    • Henry Schein Reports First Quarter 2025 Financial Results

      First-quarter 2025 GAAP diluted EPS of $0.88, growth of 22% compared to the first quarter of 2024 First-quarter 2025 non-GAAP diluted EPS of $1.15, growth of 4.5% compared to the first quarter of 2024 Maintains guidance for 2025 non-GAAP diluted EPS of $4.80 to $4.94, mid-single digit 2025 Adjusted EBITDA growth, and sales growth of 2% to 4% Repurchased $161 million of common stock, or approximately 2.3 million shares Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the first quarter ended March 29, 2025. "We are pleased with our first quarter financial re

      5/5/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein to Webcast First Quarter 2025 Conference Call on Monday, May 5th, 2025, at 8:00 a.m. ET

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, announced today that it will release its first quarter 2025 financial results before the stock market opens on Monday, May 5th, 2025, and will provide a live webcast of its earnings conference call on the same day beginning at 8:00 a.m. Eastern time. Speakers on the call will include Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, and Ronald N. South, Senior Vice President and Chief Financial Officer. Investors can access the call by visiting https://investor.henryschein.com/webcasts. A replay will be available on

      4/8/25 6:30:00 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Detailed 2025 Financial Guidance

      Fourth-quarter 2024 GAAP diluted EPS of $0.74 and non-GAAP diluted EPS of $1.19 Fourth-quarter 2024 operating cash flow of $204 million; full-year 2024 operating cash flow of $848 million, up $348 million compared with 2023 2025 non-GAAP diluted EPS expected to be in the range of $4.80 to $4.94 with mid-single digit 2025 Adjusted EBITDA growth Announces new reportable segments to provide more meaningful information for investors Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today reported financial results for the fourth quarter and full year ended December 28, 2024. The financial result

      2/25/25 6:00:00 AM ET
      $HSIC
      Medical Specialities
      Health Care

    $HSIC
    Leadership Updates

    Live Leadership Updates

    See more

    $HSIC
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $HSIC
    SEC Filings

    See more
    • Henry Schein Announces Completion of Strategic Investment by KKR and Appointment of Dan Daniel to Board of Directors

      Henry Schein, Inc. (NASDAQ:HSIC), the world's largest provider of health care solutions to office-based dental and medical practitioners, today announced the successful completion of a $250 million strategic investment by funds affiliated with KKR, a leading global investment firm. Upon the closing of this transaction, KKR has become the holder of approximately 12% of the common shares of Henry Schein. In connection with the investment, William K. "Dan" Daniel, Executive Advisor to KKR and former Executive Vice President of Danaher Corporation, has officially joined Henry Schein's Board of Directors as an independent director. He joins Max Lin, Partner at KKR and leader of the firm's Healt

      5/16/25 4:10:00 PM ET
      $HSIC
      $KKR
      Medical Specialities
      Health Care
      Investment Managers
      Finance
    • PureTech Founded Entity Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience PureTech Health plc (NASDAQ:PRTC, LSE: PRTC)) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted that its Founded Entity, Seaport Therapeutics, ("Seaport") a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthca

      3/11/25 7:05:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Seaport Therapeutics Appoints Robert J. Hombach to its Board of Directors as Audit Committee Chair

      Former Baxter and Baxalta Chief Financial Officer brings more than 30 years of biotech financial and operational experience Seaport Therapeutics ("Seaport" or the "Company"), a clinical-stage biopharmaceutical company that is advancing novel neuropsychiatric medicines with a proven strategy and team, today announced that Robert "Bob" J. Hombach has been appointed to its Board of Directors and will serve as the Chair of the Audit Committee. Mr. Hombach is a seasoned financial and operational executive with three decades of high-level leadership in the healthcare sector. His experience includes serving on the Audit, Finance and Compensation Committees for several public and private Boards of

      3/11/25 7:00:00 AM ET
      $BAX
      $BMRN
      $EMBC
      $HSIC
      Medical/Dental Instruments
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Medical Specialities
    • Wells Fargo initiated coverage on Henry Schein with a new price target

      Wells Fargo initiated coverage of Henry Schein with a rating of Equal Weight and set a new price target of $80.00

      2/14/25 7:05:26 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein upgraded by BofA Securities with a new price target

      BofA Securities upgraded Henry Schein from Underperform to Buy and set a new price target of $84.00 from $69.00 previously

      1/6/25 8:12:21 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • Mizuho initiated coverage on Henry Schein with a new price target

      Mizuho initiated coverage of Henry Schein with a rating of Neutral and set a new price target of $75.00

      12/4/24 7:41:29 AM ET
      $HSIC
      Medical Specialities
      Health Care
    • SEC Form DEFA14A filed by Henry Schein Inc.

      DEFA14A - HENRY SCHEIN INC (0001000228) (Filer)

      5/16/25 4:10:22 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Henry Schein Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure

      8-K - HENRY SCHEIN INC (0001000228) (Filer)

      5/16/25 4:07:05 PM ET
      $HSIC
      Medical Specialities
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Henry Schein Inc.

      SCHEDULE 13D/A - HENRY SCHEIN INC (0001000228) (Subject)

      5/6/25 4:15:28 PM ET
      $HSIC
      Medical Specialities
      Health Care